News
Media
Puzzler
Publications
CME/CE
Resources
Conferences
Partnerships
Subscribe
Editorial

Opinion|Videos|September 11, 2024

Central Precocious Puberty in Male Patients

Author(s)Karen O. Klein, MD, Jill Samis, MD , Aviva B. Sopher, MD, MS

The panel examines potential long-term effects of central precocious puberty treatment on bone density and spermatogenesis in male patients.

Episodes in this series

3 KOLs are featured in this series.

EP. 1 Overview Of Central Precocious Puberty

3 KOLs are featured in this series.

EP. 2 Diagnosis of Central Precocious Puberty and its Psychosocial Impact

3 KOLs are featured in this series.

EP. 3 Early Diagnosis and Treatment for Central Precocious Puberty

3 KOLs are featured in this series.

EP. 4 Treatment Options for Central Precocious Puberty

3 KOLs are featured in this series.

EP. 5 Safety and Efficacy of GnRHa Treatments in Central Precocious Puberty

3 KOLs are featured in this series.

EP. 6 Individualized Management of Central Precocious Puberty

3 KOLs are featured in this series.

EP. 7 Central Precocious Puberty Treatment Starts, Discontinuations and Misconceptions

3 KOLs are featured in this series.

EP. 8 Central Precocious Puberty in Male Patients

3 KOLs are featured in this series.

EP. 9 Recommendations and Outlook for Central Precocious Puberty

Video content above is prompted by the following:

How do you address bone density concerns and spermatogenesis in a male patient with CPP?

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Trending on Contemporary Pediatrics

FAQ: Which children with early puberty actually need testing and treatment?

ACIP dropped MMRV coverage. New data show it was a lifeline for VFC-eligible kids

Douglas Mack, MD, shares details on the ongoing THRIVE study of epicutaneous immunotherapy for peanut allergy

FDA grants tegacorat orphan, rare pediatric disease status for DMD

FDA clears IND for investigational SUMF1 gene therapy in multiple sulfatase deficiency